With
the aim of reducing development costs, pharmaceutical companies face a
second, pressing challenge: to find a way to
prevent the expensive,
toxicity-triggered
failures of drug
candidates in advanced clinical trials, and to
steer away from the recent history of potentially catastrophic
misfortunes of drugs withdrawn from the market because of concealed
side effects.
Confident over the power of its new tools, the
pharmaceutical industry has indeed lowered its guard - and its standards
– when it comes to ensure that its chemistry is
compatible with the
biosphere.
At Chemylix, we
believe that the smartest strategy to improve the chances of a compound's
surviving the drug development process, as well as the early years on
the market, is to
start off with the "right" molecule in the first place.
We believe that
staying within the bounds of the biosphere
is the surest way to guard our customers from latent,
potentially fatal, toxicity issue arising down the development path.
Our
Molecular Foundry™ synthetic engine has therefore been designed around our guiding principle: "
Start Smart to Make it Safe".
